CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Modus Therapeutics Holding AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Modus Therapeutics Holding AB
Olof Palmes gata 29 IV
STOCKHOLM, 111 22  Sweden Ticker: MODTXMODTX
Business Summary
Modus Therapeutics Holding AB is a Sweden-based biotechnology company that through the patented polysaccharide sevuparin develops the treatment for severe diseases with large residual medical needs. The company's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ViktorDrvota 59 1/1/2016 1/1/2016
Chief Executive Officer JohnOhd 53 1/1/2020 1/1/2020
Chief Financial Officer ClaesLindblad 57 1/1/2021 1/1/2021
Independent Board Member Ellen K.Donnelly 50 1/1/2020 1/1/2020

Subsidiaries
Business Name Address City State/Province Country
Modus Therapeutics AB Sankt Eriksgatan 117 STOCKHOLM Sweden

Business Names
Business Name
MODTX
Modus Therapeutics AB

General Information
Number of Employees: 2 (As of 6/30/2024)
Outstanding Shares: 35,938,899 (As of 6/30/2024)
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024